NClip

Calcimimetics and Calcitonin

2 min read

Calcimimetics and Calcitonin

Key Points

  • Calcimimetics (for example cinacalcet) activate calcium-sensing receptors to reduce parathyroid hormone output and lower serum calcium.
  • Calcitonin salmon reduces serum calcium by inhibiting osteoclast activity and increasing renal calcium excretion.
  • Cinacalcet is used in primary/secondary hyperparathyroidism and selected hypercalcemia pathways.
  • Calcitonin salmon is used for hypercalcemia, postmenopausal osteoporosis, and Paget disease pathways.
  • Priority safety risks include hypocalcemia, GI intolerance, and interaction-related adverse effects.

Calcimimetics

Cinacalcet

  • Indications: primary/secondary hyperparathyroidism and selected hypercalcemia states.
  • Administration: take with meals; tablets should not be chewed, crushed, or divided.
  • Contraindication: hypersensitivity and baseline hypocalcemia risk contexts.
  • Caution: severe hepatic impairment, hypotension/heart-failure pathways, and upper-GI bleeding risk profiles.
  • Common adverse effects: nausea and vomiting.

Peptide Hormone Pathway

Calcitonin Salmon

  • Mechanism: inhibits osteoclast-mediated bone resorption and increases urinary calcium excretion.
  • Indications: hypercalcemia, postmenopausal osteoporosis, and Paget disease of bone.
  • Routes: subcutaneous/intramuscular injection and intranasal formulations (product-specific indications).
  • Injectable handling: verify solution is clear/colorless and particle-free before administration; use sterile technique and safe sharps disposal.
  • Interaction cue: may lower plasma lithium concentration by increasing urinary lithium clearance.

Nursing Assessment and Monitoring

  • Monitor calcium, phosphate, and PTH trends as ordered; escalate symptomatic hypocalcemia immediately.
  • Assess for GI intolerance, neuromuscular symptoms, and worsening fatigue/weakness.
  • For cinacalcet, monitor for symptoms compatible with excessive calcium reduction (for example cramping, paresthesia, confusion).
  • For calcitonin pathways, monitor treatment response and adverse effects; evaluate medication-interaction risk, including lithium.

Patient Education

  • Take medications exactly as prescribed and do not self-adjust dose.
  • Report persistent nausea/vomiting, muscle cramps, tingling, confusion, or worsening weakness.
  • For calcitonin injections, follow aseptic technique and proper sharps disposal training.
  • Maintain follow-up laboratory appointments for calcium and endocrine monitoring.

Graph View